Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome

Abstract

Background Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that is activated by collagens that is involved in the pathogenesis of fibrotic disorders. Interestingly, de novo production of the collagen type I (Col I) has been observed in Col4a3 knockout mice, a mouse model of Alport Syndrome (AS mice). Deletion of the DDR1 in AS mice was shown to improve survival and renal function. However, the mechanisms driving DDR1-dependent fibrosis remain largely unknown. Methods Podocyte pDDR1 levels, Collagen and cluster of differentiation 36 (CD36) expression was analyzed by Real-time PCR and Western blot. Lipid droplet accumulation and content was determined using Bodipy staining and enzymatic analysis. CD36 and DDR1 interaction was determined by co-immunoprecipitation. Creatinine, BUN, albuminuria, lipid content, and histological and morphological assessment of kidneys harvested from AS mice treated with Ezetimibe and/or Ramipril or vehicle was performed. Findings We demonstrate that Col I-mediated DDR1 activation induces CD36-mediated podocyte lipotoxic injury. We show that Ezetimibe interferes with the CD36/DDR1 interaction in vitro and prevents lipotoxicity in AS mice thus preserving renal function similarly to ramipril. Interpretation Our study suggests that Col I/DDR1-mediated lipotoxicity contributes to renal failure in AS and that targeting this pathway may represent a new therapeutic strategy for patients with AS and with chronic kidney diseases (CKD) associated with Col4 mutations. Funding This study is supported by the NIH grants R01DK117599, R01DK104753, R01CA227493, U54DK083912, UM1DK100846, U01DK116101, UL1TR000460 (Miami Clinical Translational Science Institute, National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities), F32DK115109, Hoffmann-La Roche and Alport Syndrome Foundation.

SARS-CoV-2 pneumonia—receptor binding and lung immunopathology: a narrative review

“…Finally, the cytokine profile in COVID-19 patients resembles haemophagocytic lymphohistiocytosis (HLH) syndrome [ 69 ]. The cytokine profile of HLH is characterized by high levels of IFN-γ, TNF-α, IL-6, IL-10, and IL-12 [ 70 ], a similar pattern to what is found in severe COVID-19 [ 52 , 53 , 60 , 61 ]. Other cardinal features of HLH such as cytopenias and hyperferritinemia are also a common finding in severe COVID-19 [ 51 , 61 ].…”

“…Moreover, lymphocytopenia prevalence is higher in ICU than in non-ICU patients (85 vs 54%) and is a risk factor for CARDS [ 12 , 44 , 52 ]. Decrease in lymphocyte count mainly concerns CD8 [ 53 ], CD4 and CD3 T-cells [ 15 ].…”

“…In COVID-19, the immune response is characterized by high plasma levels of interleukins (IL-6, IL-2), interferons (IFN-y,) chemokines (CXCL10, CCL2, CCL3), growth factors (granulocyte colony stimulating factor) and tumor necrosis factor (TNFα). A high level of IL-10 has also been reported; however, the level of IL-10 was lower in patients with severe COVID-19 when compared to patients with mild COVID-19 [ 52 , 53 , 60 , 61 ]. The cytokine profile in the serum is summarized in Table 3 .…”

Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review

“…Zhang et al [ 39 ] demonstrated that lymphopenia (75.4%) and eosinopenia (52.9%) were discovered in most patients. Liu et al [ 40 ] found that patients with severe symptoms exhibited continuous and obvious decreases in lymphocyte counts and increases in neutrophil counts compared to patients with mild symptoms. Compared to the mild cases, severe cases exhibited significant decreases in T cell counts as well as increases in IL-2, IL-10, IL-6, and IFN-γ levels in peripheral blood.…”

Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: an update

“…Pitt Co. Vacc, developed by the University of Pittsburgh, incorporates the use of recombinant immunogens. Even after the gamma sterilization, the vaccine was successful in maintaining its immunogenicity [ 61 ]. Triple Antigen Vaccine developed by Premas Biotech, India.…”